Lv1
40 积分 2023-06-26 加入
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2天前
已完结
Artificial intelligence in drug development
1个月前
已完结
Dual inhibition of EGFR and PI3K with a single drug
1个月前
已完结
Wild-type IDH1 maintains NSCLC stemness and chemoresistance through activation of the serine biosynthetic pathway
1个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
3个月前
已完结
Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy
4个月前
已完结
CRISPR activation and interference screens decode stimulation responses in primary human T cells
4个月前
已完结
ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites
4个月前
已完结
A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression.: Unlocking cellular and biochemical mechanisms
5个月前
已完结
CDK inhibitors from past to present: A new wave of cancer therapy
5个月前
已完结
皖公网安备34019202002308
